Stimulants work for ADHD because they increase levels of two key chemical messengers, dopamine and norepinephrine, in the parts of the brain responsible for attention, impulse control, and planning. People with ADHD have lower activity in these brain circuits, and stimulants bring that activity closer to typical levels. Between 70 and 80% of children with ADHD show fewer symptoms when taking stimulant medication, making it the most effective single treatment available.
The Dopamine Shortage in ADHD
ADHD is fundamentally a problem of brain chemistry, not willpower. The brain relies on dopamine and norepinephrine to regulate attention, filter distractions, and coordinate goal-directed behavior. In ADHD, the systems that use these chemical messengers are underactive, particularly in the prefrontal cortex, the region behind your forehead that handles executive functions like working memory, planning, impulse control, and cognitive flexibility.
Think of the prefrontal cortex as air traffic control for the brain. It decides what deserves your attention, holds information in mind while you work with it, and puts the brakes on impulsive responses. When dopamine and norepinephrine signals are too weak in this region, the result is exactly what ADHD looks like: difficulty sustaining focus, acting before thinking, trouble organizing tasks, and struggling to follow through on plans.
How Stimulants Fix the Signal
Stimulant medications raise dopamine and norepinephrine levels in the brain, but they do it in a surprisingly targeted way. At the low, clinically relevant doses used for ADHD, stimulants preferentially boost these chemical messengers in the prefrontal cortex while having much smaller effects on other brain regions. Animal studies show that doses producing blood levels similar to prescribed human doses cause prominent increases in dopamine and norepinephrine in the prefrontal cortex, with substantially smaller effects in areas associated with reward and pleasure.
This regional selectivity is key. The medication isn’t flooding the entire brain with stimulation. It’s selectively strengthening the signal in exactly the circuits that are underperforming, essentially turning up the volume on the brain’s self-regulation system.
Why a Stimulant Has a Calming Effect
The most common question people have is why a stimulant would make someone calmer and more focused rather than wired and jittery. This isn’t actually paradoxical once you understand the underlying biology. When the prefrontal cortex doesn’t have enough dopamine to function properly, subcortical brain regions (the deeper, more impulsive parts of the brain) run without adequate top-down control. Boosting dopamine in the prefrontal cortex restores that control.
Research using animal models has shown that when dopamine is depleted in the prefrontal cortex, it actually increases dopamine activity in subcortical areas and ramps up hyperactive behavior. Stimulants reverse this pattern. By elevating dopamine specifically in the prefrontal cortex, they allow the brain’s executive control center to properly regulate the rest of the system. The result looks like calming down, but what’s really happening is that the brain’s self-regulation is coming back online. This is why the same medication that might make a person without ADHD feel overstimulated helps someone with ADHD feel organized and settled.
Two Types of Stimulants
The two main classes of stimulant medication, amphetamine-based and methylphenidate-based, share the same core effect: they increase dopamine and norepinephrine in the brain. But they achieve this through somewhat different mechanisms.
Both types block the transporters that normally vacuum dopamine and norepinephrine back out of the synapse (the gap between nerve cells), letting these messengers linger longer and strengthen the signal. Amphetamines go further. They also release stored dopamine directly from nerve cells by reversing the direction of the transporter, essentially pushing dopamine out into the synapse. Amphetamines additionally slow down the enzyme that breaks dopamine apart inside nerve cells, which means more dopamine survives to be released. These extra mechanisms are why amphetamines tend to produce a more pronounced increase in dopamine compared to methylphenidate.
In practice, about 70% of people respond well to the first stimulant they try. Those who don’t respond to one class often respond to the other, which is why doctors may switch between methylphenidate and amphetamine-based options during treatment.
What Stimulants Improve
Research consistently shows that stimulants improve several specific cognitive functions in people with ADHD. These include working memory (holding information in mind while using it), reaction time, consistency of attention, and the ability to inhibit impulsive responses. Studies measuring attention performance show that children on stimulant medication make fewer errors of omission, meaning they miss fewer things they’re supposed to notice, a direct reflection of improved sustained attention.
The effects extend beyond cognitive tests into daily life. Parent and teacher rating scales show significant improvements in hyperactivity, inattention, and overall behavioral functioning. These improvements typically become noticeable within the first week of reaching an effective dose, making stimulants among the fastest-acting treatments in psychiatry.
Finding the Right Dose
Stimulant dosing is highly individual. The American Academy of Pediatrics recommends starting at a low dose and increasing weekly until the best balance is found: maximum symptom improvement with the fewest side effects. Body weight provides only a rough guideline, and the actual optimal dose varies significantly from person to person.
During this process, called titration, parents and teachers complete standardized rating scales after each dose adjustment so the prescriber can objectively track changes. Baseline measurements of heart rate, blood pressure, height, weight, and common side effects like headache, stomach discomfort, sleep difficulties, and appetite changes are taken before medication begins, then monitored throughout. The goal isn’t to eliminate every side effect but to find the dose where the benefits clearly outweigh any minor effects, which often diminish over the first few weeks.
Immediate vs. Extended Release
Both immediate-release and extended-release formulations are effective at reducing ADHD symptoms, and studies show comparable improvements on behavioral rating scales. The difference is practical. Immediate-release versions typically last 3 to 4 hours and may need to be taken two or three times daily. Extended-release formulations use specialized delivery systems that gradually release the medication over 8 to 12 hours, requiring only a single morning dose.
Extended-release versions avoid the need for a midday dose at school or work and provide more consistent symptom coverage throughout the day. They also reduce the “crash” effect that some people experience as an immediate-release dose wears off. For children, not needing a school nurse to administer a lunchtime dose can make a meaningful difference in privacy and consistency.
Response Rates Across Age Groups
In children, controlled studies consistently show a response rate of about 70 to 80%. Adults with ADHD also benefit, though the numbers are slightly more variable: short-term controlled trials show a weighted average response rate of about 60%, while longer-term studies show improvement climbing to around 74%. The gap may partly reflect the challenges of diagnosing and treating ADHD in adults, who often have coexisting conditions and more complex lives that make isolating medication effects harder.
For children under 6, the AAP recommends trying behavioral therapy before medication, because the evidence for stimulant effectiveness is weaker in very young children and the potential for side effects is greater. From age 6 onward, guidelines recommend combining medication with behavioral therapy for the best outcomes.
Long-Term Cardiovascular Considerations
Stimulants do modestly increase heart rate and blood pressure, which has raised questions about cardiovascular safety with years of use. A large study published in JAMA Psychiatry found that more than five years of ADHD medication use was associated with a 23% increased risk of cardiovascular disease compared to nonuse. The association was driven mainly by hypertension and arterial disease, with no significant link to other cardiovascular events like heart attacks or strokes. For most people, this level of risk is considered manageable, particularly when weighed against the well-documented consequences of untreated ADHD, including higher rates of accidents, substance use, and occupational difficulties. Routine monitoring of blood pressure and heart rate remains a standard part of ongoing care.